<DOC>
	<DOC>NCT00149877</DOC>
	<brief_summary>Tegaserod (HTF919) is an aminoguanidine indole compound and a member of a new class of subgroup-selective 5-hydroxytryptamine (5-HT) agonists. The aim of this study is to investigate the efficacy, safety and tolerability of tegaserod on bowel habits in patients with CC.</brief_summary>
	<brief_title>Efficacy, Safety and Tolerability of Tegaserod in Patients With Chronic Constipation</brief_title>
	<detailed_description />
	<mesh_term>Constipation</mesh_term>
	<mesh_term>Tegaserod</mesh_term>
	<criteria>Male and females of at least 18 years of age A 12month history of constipation (defined as &lt; three spontaneous bowel movements per week and â‰¥1 of the following symptoms &gt;25% of the time: hard stools, sensation of incomplete evacuation and straining) Patients with cancer, inflammatory bowel disease or other structural bowel disease Patients who participated in a prior tegaserod study Evidence of cathartic colon or laxative abuse, pelvic floor dysfunction or neurological disorders Other protocoldefined inclusion/exclusion criteria may apply.</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>January 2008</verification_date>
	<keyword>Chronic constipation, tegaserod</keyword>
</DOC>